NCT00829504View on ClinicalTrials.gov

Ropinirole 0.25 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions
Healthy
Interventions
DRUG

Ropinirole HCl 0.25 mg Tablets

1 x 0.25 mg

DRUG

Requip® 0.25 mg Tablets

1 x 0.25 mg

Trial Locations (1)

77042

Novum Pharmaceutical Research Services, Houston

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00829504 - Ropinirole 0.25 mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter